A Phase 3 interventional study of Tocilizumab and Placebo to tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 236 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-26.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 10 that started in 2009, is one of 65 in phase 3, and was the 26th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,162 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 141 interventional ones that give a count, is one of 22 that started in 2009, is one of 85 in phase 3, and was the 70th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, parallel group study will assess the safety, disease remission, and prevention of structural joint damage in patients with early moderate to severe rheumatoid arthritis treated with tocilizumab as monotherapy or in combination with methotrexate, versus methotrexate alone. Patients will be randomized to receive either (A) tocilizumab (8 mg/kg iv every 4 weeks) plus placebo, (B) tocilizumab (8 mg/kg iv every 4 weeks) plus methotrexate (7.5-20 mg po weekly), (C) tocilizumab (4 mg/kg iv every 4 weeks) plus methotrexate (7.5-20 mg po weekly), or (D) placebo plus methotrexate (7.5-20 mg po weekly). Patients in groups C and D who have not achieved low disease activity at week 52 can receive tocilizumab 8 mg/kg iv every 4 weeks. Anticipated time on study treatment is 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
Drug: Tocilizumab · Drug: Placebo to methotrexate
Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
Drug: Tocilizumab · Drug: Methotrexate
Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
Drug: Tocilizumab · Drug: Methotrexate
Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
Drug: Placebo to tocilizumab · Drug: Methotrexate
Tocilizumab was supplied in vials.
Also known as: RoActemra, Actemra
Placebo to tocilizumab was supplied in vials.
Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
Patients received placebo to methotrexate orally once a week.
Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24
A participant has a DAS28 remission response if their DAS28 \< 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Week 24
Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52
Time frame: Week 52
Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52
Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.
Time frame: Baseline to Weeks 24 and 52
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52
The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
Time frame: Baseline to Week 52
Change From Baseline in Modified Sharp Erosion Score at Week 52
Time frame: Baseline to Week 52
Change From Baseline in Sharp Joint Space Narrowing Score at Week 52
Time frame: Baseline to Week 52
Percentage of Participants With a Major Clinical Response at Week 52
A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.
Time frame: Baseline to Week 52
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52
The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Time frame: Baseline to Weeks 24 and 52
Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52
The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.
Time frame: Baseline to Weeks 24 and 52
| Milestone | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Started | 289 | 290 | 291 | 292 |
| Completed | 226 | 231 | 227 | 236 |
| Not completed | 63 | 59 | 64 | 56 |
| Withdrew: Adverse event | 16 | 25 | 47 | 31 |
| Withdrew: Death | 2 | 4 | 2 | 1 |
| Withdrew: Insufficient therapeutic response | 21 | 7 | 2 | 9 |
| Withdrew: Violation of selection criteria at entry | 3 | 5 | 2 | 0 |
| Withdrew: Other protocol violation | 2 | 0 | 1 | 0 |
| Withdrew: Refused treatment | 13 | 13 | 5 | 8 |
| Withdrew: Failure to return | 5 | 4 | 3 | 6 |
| Withdrew: Reason not specified | 1 | 1 | 2 | 1 |
A participant has a DAS28 remission response if their DAS28 \< 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| Percentage of participants | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24 | 15.0 (10.9 to 19.1) | 31.9 (26.6 to 37.3) | 44.8 (39.1 to 50.6) | 38.7 (33.1 to 44.3) |
| Percentage of participants | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52 | 19.5 | 34.0 | 49.0 | 39.4 |
Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.
| Percentage of participants | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Week 24: ACR 20 | 65.2 | 73.6 | 74.5 | 70.2 |
| Week 24: ACR 50 | 43.2 | 47.9 | 56.9 | 47.6 |
| Week 24: ACR 70 | 25.4 | 34.7 | 38.6 | 30.1 |
| Week 52: ACR 20 | 57.1 | 62.8 | 67.2 | 63.0 |
| Week 52: ACR 50 | 40.8 | 52.4 | 55.9 | 49.3 |
| Week 52: ACR 70 | 28.9 | 37.2 | 43.1 | 36.0 |
The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
| Units on a scale | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 | 1.14 ± 4.297 | 0.42 ± 2.929 | 0.08 ± 2.090 | 0.26 ± 1.876 |
| Units on a scale | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Change From Baseline in Modified Sharp Erosion Score at Week 52 | 0.63 ± 2.556 | 0.25 ± 1.686 | 0.05 ± 1.736 | 0.15 ± 1.544 |
| Units on a scale | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Change From Baseline in Sharp Joint Space Narrowing Score at Week 52 | 0.51 ± 2.362 | 0.17 ± 1.645 | 0.03 ± 0.751 | 0.11 ± 1.046 |
A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.
| Percentage of participants | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Percentage of Participants With a Major Clinical Response at Week 52 | 16 | 22 | 31 | 22 |
The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
| Units on a scale | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Week 24 (n=246, 255, 250, 265) | -0.71 ± 0.718 | -0.92 ± 0.736 | -0.91 ± 0.695 | -0.82 ± 0.739 |
| Week 52 (n=214, 227, 228, 230) | -0.76 ± 0.800 | -1.00 ± 0.795 | -0.97 ± 0.700 | -0.87 ± 0.776 |
The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.
| Units on a scale | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Week 24 (n=237, 247, 246, 255) | 9.35 ± 9.763 | 11.33 ± 9.282 | 12.13 ± 9.263 | 10.75 ± 10.055 |
| Week 52 (n=204, 225, 221, 224) | 10.72 ± 10.389 | 12.27 ± 10.509 | 13.52 ± 9.848 | 11.73 ± 10.691 |
Collected over Adverse events were reported from Baseline through Week 52.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo to Tocilizumab + Methotrexate | — | 24/282 (8.5%) | 177/282 (62.8%) |
| Tocilizumab 4 mg/kg + Methotrexate | — | 29/289 (10%) | 182/289 (63%) |
| Tocilizumab 8 mg/kg + Methotrexate | — | 31/290 (10.7%) | 201/290 (69.3%) |
| Tocilizumab 8 mg/kg + Placebo to Methotrexate | — | 25/292 (8.6%) | 163/292 (55.8%) |
| Event | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/282 | 4/289 | 1/290 | 1/292 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/282 | 0/289 | 2/290 | 4/292 |
| AppendicitisInfections and infestations | 0/282 | 0/289 | 3/290 | 0/292 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/282 | 0/289 | 0/290 | 0/292 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/282 | 2/289 | 0/290 | 0/292 |
| CellulitisInfections and infestations | 0/282 | 1/289 | 1/290 | 2/292 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/282 | 0/289 | 0/290 | 2/292 |
| BronchopneumoniaInfections and infestations | 1/282 | 1/289 | 1/290 | 0/292 |
| Appendicitis perforatedInfections and infestations | 1/282 | 0/289 | 0/290 | 0/292 |
| Pneumonia influenzalInfections and infestations | 1/282 | 0/289 | 0/290 | 0/292 |
| Event | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 29/282 | 39/289 | 55/290 | 22/292 |
| NauseaGastrointestinal disorders | 46/282 | 41/289 | 43/290 | 19/292 |
| Upper respiratory tract infectionInfections and infestations | 40/282 | 37/289 | 30/290 | 39/292 |
| NasopharyngitisInfections and infestations | 38/282 | 40/289 | 28/290 | 27/292 |
| Transaminases increasedInvestigations | 23/282 | 35/289 | 40/290 | 22/292 |
| HypertensionVascular disorders | 21/282 | 16/289 | 23/290 | 25/292 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 21/282 | 9/289 | 16/290 | 10/292 |
| HeadacheNervous system disorders | 12/282 | 20/289 | 18/290 | 20/292 |
| BronchitisInfections and infestations | 6/282 | 18/289 | 20/290 | 8/292 |
| DiarrhoeaGastrointestinal disorders | 18/282 | 16/289 | 19/290 | 18/292 |
Baseline Characteristics were based on the intent-to-treat (ITT) population. Five of 1162 randomized patients (2 placebo + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations. The ITT population therefore included 1157 patients.
| Age, Continuous(years) | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate | Total |
|---|---|---|---|---|---|
| Mean | 49.6 ± 13.10 | 51.2 ± 13.84 | 49.5 ± 13.70 | 49.9 ± 13.22 | 50.1 ± 13.47 |
| Sex: Female, Male(Participants) | Placebo to Tocilizumab + Methotrexate | Tocilizumab 4 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Methotrexate | Tocilizumab 8 mg/kg + Placebo to Methotrexate | Total |
|---|---|---|---|---|---|
| Female | 229 | 228 | 228 | 219 | 904 |
| Male | 58 | 60 | 62 | 73 | 253 |
Showing the first 100 of 236 sites across 36 countries. Choose a country and city above to see the rest.
Ran from Oct 2009 to primary completion in May 2012, 31 months.
Results were first posted in Jul 2013, 1 year 1 month after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Methotrexate